BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer

Autor: Byung-Ho Nam, Jeong Eon Lee, Jong Won Lee, Gyungyub Gong, Peter D Beitsch, Sei Hyun Ahn, Jinil Han, Mi Jeong Kwon, Seok Jin Nam, Sae Byul Lee, Young Kee Shin
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Adjuvant Chemotherapy
Physiology
Receptor
ErbB-2
medicine.medical_treatment
Cancer Treatment
lcsh:Medicine
Kaplan-Meier Estimate
Biochemistry
Metastasis
0302 clinical medicine
Risk Factors
Breast Tumors
Medicine and Health Sciences
lcsh:Science
Aged
80 and over
Multidisciplinary
Pharmaceutics
Hazard ratio
Hormonal Therapy
Middle Aged
Prognosis
Body Fluids
Bioassays and Physiological Analysis
Receptors
Estrogen
Hormone receptor
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Lymphatic Metastasis
Hormone Bioassays
Hormonal therapy
Female
Lymph
Anatomy
Receptors
Progesterone
Research Article
Clinical Oncology
Adult
medicine.medical_specialty
Breast Neoplasms
Research and Analysis Methods
Disease-Free Survival
03 medical and health sciences
Cancer Chemotherapy
Breast cancer
Drug Therapy
Asian People
Internal medicine
Breast Cancer
Republic of Korea
medicine
Chemotherapy
Humans
Aged
Proportional Hazards Models
business.industry
Proportional hazards model
lcsh:R
Cancers and Neoplasms
Biology and Life Sciences
medicine.disease
Hormones
030104 developmental biology
lcsh:Q
Hormone therapy
Clinical Medicine
business
Biochemical Analysis
Zdroj: PLoS ONE
PLoS ONE, Vol 13, Iss 11, p e0207155 (2018)
ISSN: 1932-6203
Popis: The Breast Cancer Test (BCT) score has been validated for its ability to predict the risk of distant metastasis in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This study aimed to examine the value of the BCT score for predicting the benefit of adjuvant chemotherapy for Korean women with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. The study included 346 patients treated with either hormone therapy alone (n = 203) or hormone therapy plus chemotherapy (n = 143), and compared patient survival between the two treatment groups. The effect of BCT score on patient survival by treatment group was assessed using Cox proportional hazards models. Based on the results, the BCT score was prognostic for distant metastasis-free survival and breast cancer-specific survival in the hormone therapy alone group. There was no significant difference between the treatment groups in terms of 10-year distant metastasis-free survival in the overall patient population. However, when patients were classified as low risk (n = 266) and high risk (n = 80) according to the BCT score, addition of adjuvant chemotherapy to hormone therapy for patients classified as BCT high-risk group led to a significant improvement in 10-year distant metastasis-free survival, from 65.4% to 91.9% (hazard ratio, 0.18; 95% confidence interval, 0.05-0.64; P = 0.003); in contrast, there was no benefit for the BCT low-risk group. The stratification of patients according to the BCT score also identified clinically high-risk patients who may not benefit from chemotherapy. Results were similar for breast cancer-specific survival. In conclusion, the BCT score was not only of prognostic value but was also a predictor of chemotherapy benefit for Korean patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje